Trends in price, spending, and utilization of omalizumab among Medicare beneficiaries
© 2023 ARS-AAOA, LLC..
KEY POINTS: Between January 2005 and January 2023, the average selling price of omalizumab increased by nearly 60%. Between 2016 and 2021, Medicare Part B and D spending on omalizumab totaled over $3.7 billion. Between 2016 and 2021, Medicare Part B and D utilization of omalizumab increased by approximately 30%.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
International forum of allergy & rhinology - 13(2023), 11 vom: 17. Nov., Seite 2105-2108 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dattilo, Lillian W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologics |
|---|
| Anmerkungen: |
Date Revised 23.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/alr.23185 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357016092 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357016092 | ||
| 003 | DE-627 | ||
| 005 | 20231226071701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/alr.23185 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357016092 | ||
| 035 | |a (NLM)37199046 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dattilo, Lillian W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trends in price, spending, and utilization of omalizumab among Medicare beneficiaries |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023 ARS-AAOA, LLC. | ||
| 520 | |a KEY POINTS: Between January 2005 and January 2023, the average selling price of omalizumab increased by nearly 60%. Between 2016 and 2021, Medicare Part B and D spending on omalizumab totaled over $3.7 billion. Between 2016 and 2021, Medicare Part B and D utilization of omalizumab increased by approximately 30% | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Medicare | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a biosimilars | |
| 650 | 4 | |a chronic rhinosinusitis | |
| 650 | 4 | |a cost | |
| 650 | 4 | |a nasal polyps | |
| 650 | 4 | |a omalizumab | |
| 650 | 4 | |a price | |
| 650 | 4 | |a utilization | |
| 700 | 1 | |a Rathi, Vinay K |e verfasserin |4 aut | |
| 700 | 1 | |a Schlosser, Rodney J |e verfasserin |4 aut | |
| 700 | 1 | |a Soler, Zachary M |e verfasserin |4 aut | |
| 700 | 1 | |a Scangas, George A |e verfasserin |4 aut | |
| 700 | 1 | |a Workman, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, Stacey T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International forum of allergy & rhinology |d 2011 |g 13(2023), 11 vom: 17. Nov., Seite 2105-2108 |w (DE-627)NLM209105178 |x 2042-6984 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:11 |g day:17 |g month:11 |g pages:2105-2108 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/alr.23185 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 11 |b 17 |c 11 |h 2105-2108 | ||